
May 14 (Reuters) - Quoin Pharmaceuticals Ltd 2EB0y.F:
QUOIN PHARMACEUTICALS ANNOUNCES INITIAL POSITIVE CLINICAL DATA FOR QRX003 FROM PEDIATRIC PEELING SKIN SYNDROME STUDY
QUOIN PHARMACEUTICALS LTD - CLEAR IMPROVEMENT IN PATIENT'S SKIN AFTER 12 WEEKS
QUOIN PHARMACEUTICALS LTD: QRX003 IS BEING WELL TOLERATED AND NO ADVERSE EVENTS HAVE BEEN REPORTED
Further company coverage: [2EB0y.F]